Biofil Chemicals and Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Biofil Chemicals and Pharmaceuticals has a total shareholder equity of ₹184.0M and total debt of ₹4.6M, which brings its debt-to-equity ratio to 2.5%. Its total assets and total liabilities are ₹420.4M and ₹236.4M respectively. Biofil Chemicals and Pharmaceuticals's EBIT is ₹6.8M making its interest coverage ratio 21.4. It has cash and short-term investments of ₹2.2M.
Key information
2.5%
Debt to equity ratio
₹4.55m
Debt
| Interest coverage ratio | 21.4x |
| Cash | ₹2.20m |
| Equity | ₹183.97m |
| Total liabilities | ₹236.44m |
| Total assets | ₹420.40m |
Recent financial health updates
No updates
Recent updates
Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 01
Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Shares Climb 60% But Its Business Is Yet to Catch Up
Sep 18
There's Reason For Concern Over Biofil Chemicals and Pharmaceuticals Limited's (NSE:BIOFILCHEM) Price
Sep 03Getting In Cheap On Biofil Chemicals and Pharmaceuticals Limited (NSE:BIOFILCHEM) Is Unlikely
Jul 18Financial Position Analysis
Short Term Liabilities: BIOFILCHEM's short term assets (₹336.1M) exceed its short term liabilities (₹232.9M).
Long Term Liabilities: BIOFILCHEM's short term assets (₹336.1M) exceed its long term liabilities (₹3.6M).
Debt to Equity History and Analysis
Debt Level: BIOFILCHEM's net debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: BIOFILCHEM's debt to equity ratio has reduced from 9.9% to 2.5% over the past 5 years.
Debt Coverage: BIOFILCHEM's debt is well covered by operating cash flow (73.6%).
Interest Coverage: BIOFILCHEM's interest payments on its debt are well covered by EBIT (21.4x coverage).